AirSculpt Technologies, Inc. is a healthcare company that provides minimally invasive body contouring procedures. Operating primarily under the Elite Body Sculpture brand, the company utilizes its proprietary AirSculpt technology to remove fat and tighten skin without the use of needles, scalpels, or general anesthesia. The company operates a network of over 30 specialized clinics across the United States, Canada, and the United Kingdom.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
151,818
180,350
195,917
168,794
Cost of Sales
61,690
71,149
73,773
62,781
Gross Profit
90,128
109,201
122,144
106,013
Selling, General & Administrative Expenses
82,180
98,880
102,381
101,418
Depreciation & Amortization Expenses
12,781
11,888
10,253
8,061
Other Operating Expenses
6,727
16
(212)
147
Operating Profit
(11,560)
(1,583)
9,722
(4,545)
Interest Expense
(6,078)
(6,247)
(6,485)
(6,751)
Non-Operating Income
—
—
—
932
Total Non-Operating Income
(6,078)
(6,247)
(6,485)
(5,819)
Income Before Provision for Income Taxes
(17,638)
(7,830)
3,237
(11,296)
Provision for Income Taxes
(5,971)
188
7,477
3,383
Consolidated Net Income
(11,667)
(8,018)
(4,240)
(14,679)
Net Income Attributable to Common Shareholders
(11,667)
(8,018)
(4,240)
(14,679)
Basic EPS
-0.19
-0.14
-0.08
-0.26
Diluted EPS
-0.19
-0.14
-0.08
-0.26
Basic Weighted Average Shares Outstanding
60,451
57,689
56,779
55,685
Diluted Weighted Average Shares Outstanding
60,451
57,689
56,779
55,685
Shares Outstanding
64,456
58,369
57,356
56,182
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
8,449
8,235
10,262
9,616
Total Cash and Cash Equivalents
8,449
8,235
10,262
9,616
Other Receivables
1,499
3,056
1,941
2,831
Total Trade Receivables
1,499
3,056
1,941
2,831
Other Current Assets
5,508
5,826
3,758
4,229
Total Current Assets
15,456
17,117
15,961
16,676
Net Property, Plant & Equipment
50,268
66,910
54,321
47,970
Net Intangible Assets
36,839
41,592
46,346
51,099
Goodwill
81,734
81,734
81,734
81,734
Other Long-Term Assets
3,007
5,428
5,657
3,280
Total Assets
187,304
212,781
204,019
200,759
Accounts Payable
5,368
6,256
3,922
3,844
Accrued Expenses
7,905
10,835
7,430
9,635
Current Portion of Long-Term Debt
5,460
4,250
2,125
2,125
Current Portion of Leases
7,298
6,439
5,375
4,356
Unearned Revenue
1,871
1,169
1,463
2,358
Total Current Liabilities
27,902
28,949
20,315
22,318
Long-Term Debt
50,585
70,456
69,503
81,420
Leases
20,227
27,795
22,665
19,745
Other Long-Term Liabilities
878
7,393
7,544
6,510
Total Long-Term Liabilities
71,690
105,644
99,712
107,675
Total Liabilities
99,592
134,593
120,027
129,993
Common Stock
64
58
57
56
Additional Paid-in Capital
128,315
107,721
103,898
85,858
Accumulated Other Comprehensive Income
(96)
(687)
(412)
(76)
Retained Earnings
(40,571)
(28,904)
(19,551)
(15,072)
Total Common Shareholders' Equity
87,712
78,188
83,992
70,766
Total Shareholders' Equity
87,712
78,188
83,992
70,766
Total Liabilities and Shareholders' Equity
187,304
212,781
204,019
200,759
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
(11,667)
(8,018)
(4,240)
(14,679)
Depreciation & Amortization
12,781
11,888
10,253
8,061
Share-Based Compensation Expense
2,331
3,762
18,224
29,457
Other Adjustments
1,338
103
1,337
3,134
Changes in Accounts Payable
579
739
(206)
865
Changes in Accrued Expenses
(6,786)
9,225
2,839
8,171
Changes in Unearned Revenue
735
(293)
(896)
(452)
Changes in Other Operating Activities
3,785
(6,056)
(3,355)
(10,110)
Cash from Operating Activities
3,096
11,350
23,956
24,447
Capital Expenditure
(2,404)
(14,007)
(9,919)
(12,921)
Cash from Investing Activities
(2,404)
(14,007)
(9,919)
(12,921)
Repayments of Short-Term Debt
(5,000)
5,000
—
—
Net Issuance / (Repayments) of Short-Term Debt
(5,000)
5,000
—
—
Issuance of Long-Term Debt
—
—
—
83,503
Repayments of Long-Term Debt
(13,793)
(2,125)
(12,125)
(84,263)
Net Issuance / (Repayments) of Long-Term Debt
(13,793)
(2,125)
(12,125)
(760)
Issuance of Common Shares
18,764
—
—
—
Repurchases of Common Shares
(56)
(903)
(233)
(2,031)
Net Issuance / (Repurchases) of Common Shares
18,708
(903)
(233)
(2,031)
Common Share Dividends Paid
—
(252)
(464)
(24,319)
Other Financing Activities
(393)
(1,090)
(569)
(147)
Cash from Financing Activities
(478)
630
(13,391)
(27,257)
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash